VYT.MC Vytrus Biotech S.A.

Healthcare Biotechnology Madrid Exchange
14.30 EUR
Close of Oct 31, 2026
6.40 20.60
Market cap
EUR 108M
P/E
26.0x
P/B
8.33x
ROE
28.1%
Dividend yield
-
Fundamental score
3.2/5

Ratios use the latest price and the fiscal year ending Dec 2025.

Is VYT.MC undervalued?

Graham number

The Graham number of Vytrus Biotech S.A. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vytrus Biotech S.A. fundamental analysis

14 of 22 checks passed

ROE 2/2

High return on equity (28.1%), above 20%.

ROA 1/1

Return on assets (19.8%) is above the industry median (-1.9%).

Profit Consistency 2/2

Profitable for 6 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (184.0%) is above the 5-year average (66.1% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (184.0%) is above the industry median (41.0%).

Revenue Growth 2/2

Revenue grew 31.5% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (15.0%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

No interest expense reported.

PE vs Market 0/1

PE (26.0x) is above the market median (16.3x).

PE vs Industry 0/1

PE (26.0x) is above the industry median (18.6x).

PBV 0/1

Price to book (8.3x) is above the industry median (2.0x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 216.7, limit 22.5).

PEG 1/1

PEG on 5-year earnings growth is 0.39, growth is cheap.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Vytrus Biotech S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vytrus Biotech S.A.

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum …

Full company profile